Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD) [Phase 3]

View source ↗

Summary

A Phase 3 study to evaluate the safety and efficacy of Zilganersen (ION373) in patients with Alexander disease is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alexander Disease

Drugs mentioned

• Zilganersen

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Alexander Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING